CRISPR Therapeutics AG - Common Stock (CRSP)

Q4 2024 13F Holders as of 12/31/2024

Type / Class
Equity / Common Stock
Shares outstanding
86M
Number of holders
394
Total 13F shares, excl. options
64.4M
Shares change
+5.41M
Total reported value, excl. options
$2.54B
Value change
+$195M
Put/Call ratio
1.26
Number of buys
154
Number of sells
-184
Price
$39.36

Significant Holders of CRISPR Therapeutics AG - Common Stock (CRSP) as of Q4 2024

505 filings reported holding CRSP - CRISPR Therapeutics AG - Common Stock as of Q4 2024.
CRISPR Therapeutics AG - Common Stock (CRSP) has 394 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 64.4M shares of 86M outstanding shares and own 74.95% of the company stock.
Largest 10 shareholders include ARK Investment Management LLC (8.97M shares), Capital International Investors (8.74M shares), T. Rowe Price Investment Management, Inc. (3.81M shares), BlackRock, Inc. (2.76M shares), Nikko Asset Management Americas, Inc. (2.75M shares), Sumitomo Mitsui Trust Group, Inc. (2.75M shares), STATE STREET CORP (2.49M shares), FMR LLC (2.22M shares), UBS Group AG (1.98M shares), and VANGUARD GROUP INC (1.74M shares).
This table shows the top 394 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.